Postoperative Venous Thromboembolism Predicts Survival in Cancer Patients
- 1 May 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 255 (5), 963-970
- https://doi.org/10.1097/sla.0b013e31824daccb
Abstract
Objectives: To determine whether a postoperative venous thromboembolism (VTE) is associated with a worse prognosis and/or a more advanced cancer stage and to evaluate the association between a postoperative VTE and cancer-specific survival when known prognostic factors, such as age, stage, cancer type, and type of surgery, are controlled. Context: It is unknown whether oncology patients who develop a venous thromboembolism after a complete curative resection are at the same survival disadvantage as oncology patients with a spontaneous VTE. Methods: A retrospective case control study was conducted at Memorial Sloan-Kettering Cancer Center. Years of study: January 1, 2000, to December 31, 2005. Median follow-up: 24.9 months (Interquartile range 13.0, 43.0). All cancer patients who underwent abdominal, pelvic, thoracic, or soft tissue procedures and those who developed a VTE within 30 days of the procedure were identified from a prospective morbidity and mortality database. Overall survival (OS) was calculated for the entire cohort. In the matched cohort, OS and disease-specific survival (DSS) were calculated for stages 0 to 3 and stages 0 to 2. Results: A total of 23,541 cancer patients underwent an invasive procedure and 474 (2%) had a postoperative VTE. VTE patients had a significantly worse 5-year OS compared to no-VTE patients (43.8% vs 61.2%; P < 0.0001); 205 VTE patients (stages 0–3) were matched to 2050 controls by age, sex, cancer type, stage, and surgical procedure. In this matched analysis, VTE patients continued to demonstrate a significantly worse prognosis with an inferior 5-year OS (54.7% vs 66.3%; P < 0.0001) and DSS (67.8% vs 79.5%; P = 0.0007) as compared to controls. The survival difference persisted in early stage disease (stage 0–2), with 5-year DSS of 82.9% versus 87.3% (P = 0.01). Conclusions: Postoperative VTE in oncology patients with limited disease and a complete surgical resection is associated with an inferior cancer survival. A postoperative VTE remains a poor prognostic factor, even when controlling for age, stage, cancer type, and surgical procedure further supporting an independent link between hypercoagulability and cancer survival.Keywords
This publication has 49 references indexed in Scilit:
- Venous thromboembolism and prognosis in cancerThrombosis Research, 2010
- Role of Tissue Factor in CancerJournal of Clinical Oncology, 2009
- Cancer, Clots and Consensus: New Understanding of an Old ProblemJournal of Clinical Oncology, 2009
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patientsAnnals of Oncology, 2007
- The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trialsJournal of Thrombosis and Haemostasis, 2007
- The Impact of Venous Thromboembolism on Risk of Death or Hemorrhage in Older Cancer PatientsJournal of General Internal Medicine, 2007
- Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcomeThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Prognostic Significance of Thrombocytosis in Node-negative Colon CancerJournal of International Medical Research, 2005
- Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cellsBlood, 2005
- Antimetastatic effects associated with platelet reduction.Proceedings of the National Academy of Sciences of the United States of America, 1968